ETF Stock Quote ESGE - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

34.375

Bid

34.32

Ask

35.60

Volume

4,954

34.345 Day's Range 34.47

0.00 52 Week Range 0.00

Previous Close

34.03

Open

34.47

Last Trade

180

34.375

Last Trade Time

Average Volume (3m)

Financial Volume

VWAP

Form 424B5 - Prospectus [Rule 424(b)(5)]

Ocugen, Inc. Announces Proposed Public Offering of Common Stock

MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and...

Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results

MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy

• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering...

Form 8-K - Current report

Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

• Established Medium Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial• DSMB Determination to Proceed with High Dose Cohort Dosing MALVERN, Pa., June 21, 2024 (GLOBE...

Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication

MALVERN, Pa., June 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy

Established Medium Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Recommends Continuing with High-Dose Cohort Dosing with Concurrent Phase 2 Dosing MALVERN, Pa., May 31...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
IMRXImmuneering Corporation	$ 1.66 (46.90%)	959.33k
CDNACareDx Inc	$ 24.60 (23.49%)	12.05k
ARYDARYA Sciences Acquisition Corporation IV	$ 7.55 (13.70%)	450
CTNTCheetah Net Supply Chain Service Inc	$ 0.3019 (11.81%)	4.04M
OCTOEightco Holdings Inc	$ 0.362 (10.53%)	102
TWKSThoughtworks Holding Inc	$ 2.93 (-15.83%)	12.72k
TENBTenable Holdings Inc	$ 39.50 (-13.98%)	16.11k
STTKShattuck Labs Inc	$ 3.53 (-11.08%)	20.64k
MDXGMiMedx Group Inc	$ 6.70 (-10.32%)	20.35k
UDMYUdemy Inc	$ 8.35 (-9.73%)	29.96k
NVDANVIDIA Corporation	$ 118.80 (1.39%)	9.74M
CTNTCheetah Net Supply Chain Service Inc	$ 0.3019 (11.81%)	4.04M
METAMeta Platforms Inc	$ 493.53 (4.04%)	2.88M
AAPLApple Inc	$ 222.08 (0.04%)	2.59M
SQQQProShares UltraPro Short QQQ	$ 8.59 (-0.12%)	2.36M